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Short Communication
Synchronisation by hydroxyurea does not affect the
sensitivity of CEM-C7 lymphoblasts to glucocorticoids
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The glucocorticoid-sensitive human lymphoblastoid
cell line CEM-C7 is a suitable model system for
studying glucocorticoid-induced cell killing in vitro,
and for investigating possible interactions between
glucocorticoids and other antileukaemic drugs
(Norman et al., 1981; Gledhill et al., 1983).
Studies of steroid-drug interactions in CEM-7
cells have revealed differences between some drugs
which act specifically in S-phase of the cell cycle.
When combined with prednisolone according to a
protocol (protocol 1) in which the S-phase drugs
were present during the final 24h of a 48h
incubation with steroid, no significant interaction
was observed between prednisolone and metho-
trexate, or between prednisolone and daunomycin.
In contrast, combination of prednisolone with
either 6-mercaptopurine (MP) or arabinofur-
anosylcytosine (Ara-C) resulted in a cell kill which
was less than predicted from the effect of each drug
acting alone (Gledhill & Norman, 1981).
Our original hypothesis to explain the
antagonism between prednisolone and the latter
two drugs consisted of two main proposals: (i) MP
and Ara-C cause an inhibition of DNA synthesis
which is, to some extent, reversible and (ii) cells
blocked in S-phase are protected from the lethal
effect of steroid. Thus, cells surviving the S-phase
block in protocol 1 would be able to resume growth
in the absence of steroid.
Measurement of cellular DNA content by flow
microfluorimetry (FMF) confirmed that Ara-C
blocked CEM-C7 cells in S-phase, and that the
block was reversible (Gledhill et al., 1983). A
second treatment protocol (protocol 2) was devised
in which the cells were exposed to steroid after
prior treatment with Ara-C alone. This procedure
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allowed cells which had been partially synchronised
in S-phase to be released, in the presence of
hormone, into phases of the cell cycle which we
presumed to be relatively more steroid sensitive. As
predicted by the hypothesis, the resultant
interaction was synergistic rather than antagonistic,
with the increase in cell kill over predicted values
coming in the first 12-18h after removal of the
block, a time when the synchronised cells had
entered GI phase.
This paper describes the interaction of
prednisolone and hydroxyurea (HU). Hydroxyurea
was tested because it is known to synchronise cells
effectively by reducing their rate of progress
through S-phase (Tobey & Crissman, 1972; Bhuyan
et al., 1973; Walters et al., 1976) and the S-phase
block is reversible after removal of the drug (Tobey
& Crissman, 1972; Bhuyan et al., 1973).
CEM-C7 cells were maintained in liquid culture
in medium RPMI 1640, supplemented with 10%
heat-inactivated foetal calf serum (Flow
Laboratories). The cortisol concentration in this
serum was 4 x 10-8M. The cells grew exponentially
at concentrations between 105 and 4 x 106m-1,
with a doubling time of -20h. Measurement of
total cell number (viable and dead) was performed
with a Coulter Counter, model DN, with 100,u
orifice, aperture current 1 and threshold 11.
The effect of HU on cell cycle progression was
examined by measuring the DNA content of
individual cells using FMF.
This procedure, based on the method of
Crissman & Tobey (1974), has been described
previously (Gledhill et al., 1983). Cell aliquots (106
cells) were fixed in 70% ethanol and stored at 40C
prior to analysis. Fixed cells were stained with
mithramycin and DNA content was measured using
a fluorescence-activated cell sorter (FACS II,
Becton Dickinson FACS Systems, Sunnyvale CA,
USA) with an argon-ion laser set at 457nm. Each
DNA profile represents the accumulated data from
104 cells. Samples taken from cell suspensions
during DNA analysis were wet-fixed and stained
using the method of Trowell (1955). These smears
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Figure 1 DNA distribution in CEM-C7 cells treated with hydroxyurea (10-4M) and then re-incubated in
drug free medium. Cellular DNA content was measured by flow microfluorimetry (FMF). Relative
fluorescence intensity is proportional to the DNA content of the cells. The first peak (channel no. 70)
represents the cells in Gl phase of the cell cycle, with a diploid DNA content. The second peak (channels
125-140) represents cells in G2 and M-phase, which have a tetraploid DNA content. Between the two peaks
are cells in S-phase with intermediate amounts of DNA. Control hydroxyurea-treated cells were examined
immediately after 24h exposure to the drug (time=0) and then during the 12h following removal of the drug
from the cell suspension. Each FMF profile has an inset giving values for: c, the total cell count x 10 5ml-;
m, the cells in mitosis (%); and v, the number ofmorphologically viable cells (%).
were used to count cells in mitosis and to identify
the dead cells, which had small, homogeneously-
stained pyknotic nuclei.
Treatment of CEM-C7 cells with HU (10-4M)
for 24h resulted in an increase in the number of
cells in S-phase (Figure 1). Lower concentrations
(10-5M) had little effect, while 5x 10-4M HU
caused an accumulation of cells at the GI/S
boundary (data not shown). After exposure to HU
(10-4M) for 24h the cells were washed and
reincubated in drug-free medium. Samples were
taken for FMF analysis during the following 12h.
The data obtained are presented in Figure 1.
Movement of cells through S-phase began almost
immediately after removal of the drug and the
synchronised cells began to divide 4-8h later. This
period of time was marked by an increase in the
number of cells in mitosis and an abrupt increase in
the total cell count.
CEM-C7 cells were treated with prednisolone and
HU using the two protocols developed in previous
investigations (Norman et al., 1978; Gledhill et al.,
1983). In protocol 1 cells were first treated for 24h
with prednisolone (10-6M) alone, and then for a
further 24h with prednisolone plus HU. In addition
to an untreated control, the effect of prednisolone
alone and HU alone was also measured. One flask
of cells was used for each control and drug
concentration. Protocol 2 consisted of an initial
treatment of CEM-C7 cells for 24h with HU alone.
The drug was then removed by washing once in
drug-free medium, and the cells were resuspended
in fresh medium, with or without prednisolone
(10-6M), for a further 48h incubation. Cell killing
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produced by HU alone was measured at the end of
the prednisolone treatment period.
The viability of cells after drug treatment was
measured by their ability to form colonies in
agarose gels (Norman et al., 1978), using a human
fibroblast feeder layer of SAL MAT cells or Detroit
532 fibroblasts (Flow Laboratories). Mean control
plating efficiency in these experiments was 48%.
Experiments were performed several times
according to both protocols, but neither revealed
any clear or consistent difference between the
observed cell survival (SAB) and the theoretical cell
survival (SA.SB), which was calculated from the
effect of each agent acting alone (Table I, Figure
2). The difference between SAB and SA.SB did not
vary significantly from zero when the drugs were
combined according to protocol 1, while the only
measureable interactions for protocol 2 was a very
small antagonistic effect manifested at low HU
concentrations. These results are clearly different
from the antagonism (protocol 1) and synergism
(protocol 2) observed with prednisolone and Ara-C
(Gledhill & Norman, 1981; Gledhill et al., 1983).
Table I Terms used to describe the interaction between
glucocorticoids and hydroxyurea.
SA =fraction ofcells surviving treatment with gluco-
corticoid
SB =fraction of cells surviving treatment with
hydroxyurea
SAB =fraction of cells surviving treatment with both
drugs
SA.SB=predicted cell survival after treatment with both
drugs
If both drugs act independently SAB=SA.SB and
SAB-SA-SB =0
If there is antagonism SAB>SA.SB and SAB-SA.SB will
be positive.
If there is synergism SAB<SA.SB and SAB -SA-SB will be
negative.
The results presented above show that HU, like
Ara-C, inhibited DNA synthesis in CEM-C7 cells,
resulting in accumulation of cells in S-phase of the
cell cycle (Figure 1). Removal of HU from the
culture medium led to a resumption of DNA
synthesis and the completion of cell division. HU
appeared to be slightly superior to Ara-C (Gledhill
et al., 1983) in both the degree of synchronisation
obtained and the speed of recovery from the S-
phase block. Similar differences have been observed
using other cell types in vitro (Bhuyan et al., 1973;
Shackney et al., 1982).
Despite this distinct and reversible synchroni-
sation of CEM-C7 cells in S-phase, there was no
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Figure 2 Summary of investigations into the
interaction of hydroxyurea with prednisolone (10-6M)
according to protocols 1 and 2 (see text). The
expression SA,D-SA.SB is used as a measurement of the
amount of interaction, with positive values indicating
antagonism and negative values indicating synergism
(Table I). Each point represents the mean + s.e., using
data from three protocol 1 experiments and six
protocol 2 experiments. Viability was determined by
measurement ofcloning efficiency.
appreciable interaction between HU and
prednisolone in either protocol 1 or protocol 2
(Figure 2). It is clear, therefore, that our original
hypothesis proposing that reversible synchroni-
sation in S-phase protects cells from simultaneous
steroid-induced killing (in protocol 1) or enhances
subsequent cell killing by steroid (protocol 2) is not
supported by this evidence.
The ability to interact with steroid probably
derives from some other property of MP and Ara-
C, a property that is not shared with the other
three drugs studied. One such property could be the
incorporation of the nucleotide derivatives of MP
and Ara-C into DNA; this has been observed in
several different cell lines (Major et al., 1981;
Momparler, 1972; Tidd & Paterson, 1974; Nelson et
al., 1975). In contrast, HU and methotrexate are
inhibitors of enzymes (ribonucleotide diphosphate
reductase and dihydrofolate reductase respectively)
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which are essential to the supply of deoxyribo-
nucleotides for polymerisation (Krakoff et al., 1968;
Bertino, 1979), while daunomycin binds tightly to
DNA by intercalation rather than incorporation
into the polynucleotide chain (Chabner et al., 1975).
Suggestions as to how incorporation of
nucleotide analogues into DNA might result in
antagonistic or synergistic interactions with gluco-
corticoids must, at this time, be largely speculative.
Some of these explanations, though, seem worthy
of future investigation: (i) Incorporated nucleotide
analogues may affect the interaction of the steroid-
receptor complex with chromatin, leading to the
antagonism found with protocol 1. Treatment of
cells with low concentrations of Ara-C causes an
increased enzymatic methylation of DNA (Boehm
& Drahovsky, 1982), and Gasson et al. (1983) have
shown that the gene(s) involved in the steroid-
induced cytolytic response in mouse lymphoma cells
can be inactivated by methylation. (ii) Nucleotide
derivatives of Ara-C and MP may be removed from
DNA chains by the normal processes of excision-
repair (Pratt & Ruddon, 1979). If these repair
functions were to be inhibited by glucocorticoids,
there could be an accumulation of the analogue
nucleotides in the replicating DNA chains, resulting
in enhanced cell killing and protocol 2 synergism.
Our own preliminary experiments with CEM-C7
cells (Maehira et al., unpublished) have shown that
steroid treatment after X-irradiation (which causes
DNA damage) results in a synergistic interaction.
To be of any clinical significance it must be
shown that these differences between S-phase drugs
are reproducible in other steroid-sensitive leukaemic
cell lines and, if possible, in human leukaemic
blood as well.
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